Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration
Posted inCardiology Clinical Updates Internal Medicine news

Obesity Severity and Cardiovascular Trajectories: Insights from the Cross-Cohort Collaboration

This review synthesizes findings from a 21- **Compiling final edits** Now that I've structured the article, I'm focusing on the final touches, particularly the content for the "Highlights," "Expert Commentary," and the "Conclusion" sections. I'm leveraging the provided literature, including the Dardari et al. study and related papers on GLP-1 agonists and dietary patterns, to build a cohesive narrative. The JSON schema is in its final phase of completion. I have successfully populated the `relative_articles` field. cohort study on 289,875 individuals, demonstrating that severe obesity (BMI ≥35 kg/m²) dramatically elevates risks for heart failure and atrial fibrillation, while revealing significant sex-based differences in stroke and mortality risk.
Angiographic Burden of Coronary Atherosclerosis: The Critical Mediator Between ASCVD Risk Factors and Cardiovascular Outcomes
Posted inCardiology Internal Medicine news

Angiographic Burden of Coronary Atherosclerosis: The Critical Mediator Between ASCVD Risk Factors and Cardiovascular Outcomes

This Mendelian randomization study reveals that coronary plaque burden significantly mediates the link between traditional risk factors and adverse events like myocardial infarction and heart failure, reinforcing the necessity of early primary prevention to intercept atherosclerosis development.
Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial
Posted inInfectious Diseases Internal Medicine news

Ensitrelvir Demonstrates Potent Antiviral Efficacy Comparable to Nirmatrelvir in Early COVID-19: Insights from the PLATCOV Trial

The PLATCOV trial identifies ensitrelvir as a highly effective oral antiviral, achieving rapid SARS-CoV-2 clearance comparable to ritonavir-boosted nirmatrelvir. This phase 2 adaptive trial suggests ensitrelvir is a viable alternative for outpatient management, potentially overcoming limitations associated with ritonavir-boosted regimens.
Minocycline Significantly Improves Functional Recovery in Acute Ischaemic Stroke: Evidence from the EMPHASIS Trial
Posted inInternal Medicine Neurology news

Minocycline Significantly Improves Functional Recovery in Acute Ischaemic Stroke: Evidence from the EMPHASIS Trial

The EMPHASIS trial reveals that oral minocycline initiated within 72 hours of an acute ischaemic stroke significantly enhances functional independence at 90 days. This multicentre study provides robust evidence for a well-tolerated, accessible neuroprotective strategy beyond the traditional reperfusion window.
Pharmacist-Led Patient Self-Testing Superior to Usual Care for Warfarin Management in Mechanical Heart Valve Patients: Evidence from a Multicentre RCT in China
Posted inCardiology Internal Medicine news

Pharmacist-Led Patient Self-Testing Superior to Usual Care for Warfarin Management in Mechanical Heart Valve Patients: Evidence from a Multicentre RCT in China

A multicentre RCT in China found that pharmacist-led patient self-testing (PST) significantly improves time in therapeutic range and reduces major bleeding and thromboembolism in patients with mechanical heart valves compared to traditional outpatient clinic care.